Search results for "pharmacogenetics."

showing 10 items of 79 documents

Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation.

2015

Aim: Studying the possible influence of SNPs on efficacy and safety of calcineurin inhibitors upon heart transplantation. Materials & methods: In 60 heart transplant patients treated with tacrolimus or cyclosporine, we studied a panel of 36 SNPs correlated with a series of clinical parameters during the first post-transplantation year. Results: The presence of serious infections was correlated to ABCB1 rs1128503 (p = 0.012), CC genotype reduced the probability of infections being also associated with lower blood cyclosporine concentrations. Lower renal function levels were found in patients with rs9282564 AG (p = 0.003), related to higher blood cyclosporine blood levels. A tendency tow…

AdultGraft RejectionMalemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentRenal functionSingle-nucleotide polymorphismInfectionsKidneyKidney Function TestsGastroenterologyPolymorphism Single NucleotideTacrolimusInternal medicineGenotypeGeneticsmedicineHumansAgedPharmacologyHeart transplantationGraft rejectionbusiness.industryMiddle AgedTacrolimusTissue DonorsCalcineurinImmunologyCyclosporineMolecular MedicineHeart TransplantationFemalebusinessPharmacogeneticsImmunosuppressive AgentsPharmacogenomics
researchProduct

Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients

2016

Pharmacogenomic testing of tuberculosis drug-metabolizing enzyme genes was proposed as a strategy to identify patients at risk for suboptimal responses to medications. However, variations of the genotype frequencies among ethnic groups exist and new alleles are been identified. The aim of this study was to identify polymorphisms of genes encoding metabolic enzymes NAT2 and GSTM1 in tuberculosis patients in Latvia and to estimate the frequency of NAT2 slow acetylator and GSTM1 null genotypes. In total, 85 DNA samples were genotyped, all individuals were Caucasian. An ethnic heterogeneity reflecting the multiethnic population of the country was observed. 49 patients were Latvians, 30 were Rus…

AdultMale0301 basic medicineMicrobiology (medical)TuberculosisGenotypeArylamine N-AcetyltransferaseAntitubercular AgentsBiologyYoung Adult03 medical and health sciencesGene FrequencyGenotypeIsoniazidmedicineHumansTuberculosisPharmacology (medical)AlleleGenotypingAllele frequencyAgedGlutathione TransferaseGeneticsPolymorphism GeneticIsoniazidMiddle Agedmedicine.diseaseLatviaGenotype frequency030104 developmental biologyInfectious DiseasesFemalePharmacogeneticsmedicine.drugJournal of Infection and Chemotherapy
researchProduct

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic …

1998

Fourteen drug free healthy volunteers and 22 psychiatric patients under psychotropic medication were phenotyped for their individual CYP2D6 activity using dextromethorphan as a probe drug. A solution containing 20 mg dextromethorphan was administered and blood was taken 60 min later for determination of dextromethorphan and metabolites in serum. For comparison, urine was collected over 8 h after ingestion of 20 mg dextromethorphan in a separate test. The CYP2D6 phenotype was determined from the ratio of dextromethorphan to dextrorphan. For genotyping, mutant alleles of the CYP2D6 gene were identified using allele-specific polymerase chain reactions. Genotyping revealed five poor metabolizer…

AdultMaleCYP2D6animal structuresGenotypeMetaboliteUrineBiologyPharmacologyDextromethorphandigestive systemchemistry.chemical_compoundDextrorphanMoclobemideGeneticsmedicineHumansGeneral Pharmacology Toxicology and Pharmaceuticsskin and connective tissue diseasesGenotypingPsychotropic DrugsDextromethorphanMiddle AgedPhenotypeCytochrome P-450 CYP2D6chemistryFemalePharmacogeneticsmedicine.drugPharmacogenetics
researchProduct

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective ana…

2014

Abstract Background Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS). ABC -transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1 - and ABCG2 -genes. Results 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no associa…

AdultMaleOncologymedicine.medical_specialtyTreatment responseATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentImmunologyPrimary Progressive Multiple SclerosisPharmacologyInternal medicineGenotypeLack of efficacymedicineRetrospective analysisATP Binding Cassette Transporter Subfamily G Member 2HumansImmunology and AllergyRetrospective StudiesAnalgesicsMitoxantronebusiness.industryImmunosuppressionMiddle AgedMultiple Sclerosis Chronic ProgressiveNeoplasm Proteins3. Good healthNeurologyPharmacogeneticsATP-Binding Cassette TransportersFemaleNeurology (clinical)MitoxantronebusinessPharmacogeneticsmedicine.drugJournal of Neuroimmunology
researchProduct

Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics.

2008

Inflammation and genetics play an important role in the pathogenesis of coronary heart disease (CHD). However, despite the increasing appreciation of the role of genetics in CHD and myocardial infarction (MI) pathogenesis, pharmacogenomic approaches to uncover drug target have not been extensively explored. Cyclo-oxygenases (COXs) and 5-lipoxygenase (5-LO) are the key enzymes in the conversion of arachidonic acid to prostaglandins (PG) and leukotrienes (LT) and are implicated in a wide variety of inflammatory disorders, including atherosclerosis. In fact, PGE2 activates Matrix Metallo-proteinases whereas LTB4 is a chemoactractant for monocytes and activates gene expression in inflammatory c…

AdultMalePathologymedicine.medical_specialtymedia_common.quotation_subjectLongevityMyocardial InfarctionIMMUNOGENETICSINFARCTIONINFLAMMATIONLONGEVITYPHARMACOGENOMICSInflammationDiseaseBioinformaticsPathogenesisYoung AdultDrug Delivery SystemsRisk FactorsDrug DiscoverymedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAlleleAllelesmedia_commonAged 80 and overInflammationPharmacologyArachidonate 5-Lipoxygenasebusiness.industryAge FactorsLongevityMiddle Agedmedicine.diseasePhenotypeCyclooxygenase 2PharmacogeneticsPharmacogenomicsFemalemedicine.symptombusinessPharmacogenetics
researchProduct

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients

2011

Tacrolimus is a substrate of cytochrome P4503A (CYP3A) enzymes as well as of the drug transporter ABCB1. We have investigated the possible influence of CYP3A5 and ABCB1 single nucleotide polymorphisms (SNPs) and other factors (e.g. albumin, hematocrit and steroids) on tacrolimus blood levels achieved in a population of Caucasian liver (n=51) and kidney (n=50) transplant recipients. At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels (C0) were recorded and the weight-adjusted tacrolimus dosage (mg/kg/day) was calculated. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for genotyping CYP3A5*1 and *3 …

AdultMalemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentDNA Mutational AnalysisPopulationSingle-nucleotide polymorphismLiver transplantationBiologyKidneyPolymorphism Single NucleotideGastroenterologyBiomarkers PharmacologicalTacrolimusWhite PeopleGene FrequencyInternal medicineGeneticsmedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1educationAllele frequencyAllelesKidney transplantationAgededucation.field_of_studyKidney metabolismGeneral MedicineMiddle Agedmedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationTransplantationsurgical procedures operativeItalyLiverImmunologySettore BIO/14 - FarmacologiaPharmacogenetics CYP3A5 ABCB1 TacrolimusTransplant patientsFemaleImmunosuppressive AgentsPolymorphism Restriction Fragment LengthInternational Journal of Molecular Medicine
researchProduct

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

2006

SUMMARY Background: Venlafaxine (V) is a mixed serotoninand noradrenaline reuptake inhibitor used as afirst-line treatment of depressive disorders. It ismetabolized primarily by the highly polymorphiccytochrome P450 (CYP) enzyme CYP2D6 to yielda pharmacologically active metabolite, O-des-methylvenlafaxine (ODV), and to a lesser extentby CYP3A4, to yield N-desmethylvenlafaxine(NDV).Objectives: The aim of this study was to assesswhether the O-demethylation phenotype of V hasan impact on the pharmacokinetics and clinicaloutcome.Method: In 100 patients treated with V, serumconcentrations of V, ODV and NDV and theratios of concentrations ODV/V as a measure ofO-demethylation were determined. Indiv…

AdultMalemedicine.medical_specialtyCYP2D6AdolescentGenotypeVenlafaxine HydrochlorideVenlafaxineBiology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDesvenlafaxine SuccinateGenotypemedicineHumansPharmacology (medical)Active metaboliteAgedPharmacologyDepressive DisorderPolymorphism GeneticfungiVenlafaxine HydrochlorideMiddle AgedCyclohexanols3. Good healthEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsAntidepressive Agents Second-GenerationFemaleReuptake inhibitor030217 neurology & neurosurgeryPharmacogeneticsmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct

The experience of physicians in pharmacogenomic clinical decision support within eight German university hospitals.

2017

Aim: The aim of this study was to assess the physicians’ attitude, their knowledge and their experience in pharmacogenomic clinical decision support in German hospitals. Materials & methods: We conducted an online survey to address physicians of 13 different medical specialties across eight German university hospitals. In total, 564 returned questionnaires were analyzed. Results: The remaining knowledge gap, the uncertainty of test reimbursement and the physicians’ lack of awareness of existing pharmacogenomic clinical decision support systems (CDSS) are the major barriers for implementing pharmacogenomic CDSS into German hospitals. Furthermore, pharmacogenomic CDSS are most effective …

AdultMalemedicine.medical_specialtyDecision support systemAttitude of Health PersonnelClinical decision support systemGermanHospitals University03 medical and health sciencesYoung Adult0302 clinical medicinePhysiciansSurveys and QuestionnairesGeneticsMedicineHumans030212 general & internal medicineReimbursementAgedPharmacologybusiness.industryMiddle AgedUniversity hospitalDecision Support Systems Clinicallanguage.human_languageTest (assessment)Pharmacogenetics030220 oncology & carcinogenesisPharmacogenomicsFamily medicinelanguageMolecular MedicineFemalebusinessPharmacogenomics
researchProduct

[Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

2009

Abstract Introduction Hypersensitivity reaction to abacavir (a powerful inverse transcriptase inhibitor) is a serious adverse effect that limits its use in antiretroviral treatment and requires a high level of clinical surveillance. Certain haplotypes of the primary histocompatibility complex proteins (HLA-B*5701) are very significant predictors of the risk of hypersensitivity to this drug. The purpose of this study is to identify the cases where a probable hypersensitivity reaction to abacavir presented the HLA-B*5701 allele. Method A retrospective study was conducted in all HIV-1 positive adult patients infected treated with abacavir between January 2000 and December 2007, in Department 6…

AdultMalemedicine.medical_specialtyFeverGenotypeAnti-HIV AgentsGastrointestinal DiseasesGenes MHC Class IHIV InfectionsPharmacotherapyAbacavirInternal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseAdverse effectAgedRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedRashDideoxynucleosidesHypersensitivity reactionHLA-B AntigensImmunologyHIV-1Reverse Transcriptase InhibitorsFemaleDrug Eruptionsmedicine.symptombusinessPharmacogeneticsmedicine.drugFarmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
researchProduct

Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation.

2015

Lung transplant patients present important variability in immunosuppressant blood concentrations during the first months after transplantation. Pharmacogenetics could explain part of this interindividual variability. We evaluated SNPs in genes that have previously shown correlations in other kinds of solid organ transplantation, namely ABCB1 and CYP3A5 genes with tacrolimus (Tac) and ABCC2, UGT1A9 and SLCO1B1 genes with mycophenolic acid (MPA), during the first six months after lung transplantation (51 patients). The genotype was correlated to the trough blood drug concentrations corrected for dose and body weight (C0/Dc). The ABCB1 variant in rs1045642 was associated with significantly hig…

Adultmedicine.medical_specialtyATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatment<i>P</i>-glycoproteinSingle-nucleotide polymorphismPharmacologyP-glycoproteinGastroenterologyPolymorphism Single NucleotideCatalysisMycophenolic acidTacrolimusArticlelcsh:ChemistryInorganic ChemistryInternal medicineBlood drugmedicinelung transplantationLung transplantationCytochrome P-450 CYP3AHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopybiologyOrganic ChemistryGeneral MedicineMiddle AgedMycophenolic AcidTacrolimusMultidrug Resistance-Associated Protein 2Computer Science ApplicationsTransplantationlcsh:Biology (General)lcsh:QD1-999Pharmacogeneticsbiology.proteinMultidrug Resistance-Associated ProteinsSLCO1B1PharmacogeneticsImmunosuppressive Agentsmedicine.drugInternational journal of molecular sciences
researchProduct